Antide Acetate

1.1 Prevention of Premature LH Surge in Controlled Ovarian Stimulation (COS)

In assisted reproductive technologies such as in vitro fertilization-embryo transfer (IVF-ET), controlled ovarian stimulation relies on exogenous gonadotropins to induce synchronous development of multiple follicles. However, endogenous GnRH readily triggers a premature LH surge, leading to premature follicle luteinization, reduced oocyte quality, and lower oocyte retrieval and embryo implantation rates.

As a GnRH antagonist, antide acetate rapidly and precisely blocks pituitary GnRH receptors, completely suppressing premature LH surges without compromising follicular development.In clinical practice, it is typically administered subcutaneously starting on day 6–8 of ovarian stimulation (when the dominant follicle reaches 12–14 mm in diameter) at a daily dose of 0.25–0.5 mg, continuing until human chorionic gonadotropin (hCG) trigger day. Compared with the traditional long GnRH agonist protocol, it requires no prior pituitary downregulation, shortens the treatment cycle by 7–10 days, and avoids the initial flare-up effect (transient gonadotropin elevation) of agonists, thereby reducing the risk of ovarian hyperstimulation syndrome (OHSS).

1.2 Optimized Assisted Reproduction for Special Populations

For high responders (e.g., patients with polycystic ovary syndrome), it allows flexible dose titration combined with low-dose gonadotropins to precisely control follicular development and further lower OHSS risk. For poor responders (e.g., patients with diminished ovarian reserve), it avoids excessive pituitary suppression by agonists, preserves the auxiliary role of endogenous gonadotropins, and improves follicle recruitment efficiency.

Additionally, it serves as a standard antagonist regimen in frozen embryo transfer, intracytoplasmic sperm injection (ICSI), and other techniques for menstrual cycle regulation, ensuring synchronization between embryo transfer and endometrial development.

Endometriosis is an estrogen-dependent disorder in which ectopic endometrial tissue proliferates and bleeds repeatedly under estrogen stimulation, causing dysmenorrhea, infertility, pelvic adhesions, and other symptoms. By strongly suppressing estrogen synthesis, it maintains low systemic estrogen levels, promoting atrophy and apoptosis of ectopic endometrial tissue and alleviating clinical symptoms.

Clinical studies show that monthly injections of it for 3–6 consecutive months in endometriosis patients achieve a dysmenorrhea relief rate of over 85%, reduce pelvic nodule volume by 40%–60%, and allow rapid recovery of ovarian function after treatment cessation without impairing long-term fertility. Compared with traditional progestin therapy, it has no side effects such as breakthrough bleeding or weight gain and is better tolerated by patients.

4.1 Research on Reproductive Endocrine System Mechanisms

Antide acetate is a key tool compound for studying the function of the hypothalamic-pituitary-gonadal (HPG) axis. By selectively inhibiting GnRH receptors, it enables the establishment of gonadotropin-deficient animal models to clarify regulatory mechanisms at various levels of the HPG axis: for example, investigating the regulatory roles of LH/FSH in follicular development and spermatogenesis.

Analyzing the effects of sex hormones on reproductive organs, bone, and the cardiovascular system; and exploring crosstalk between reproductive endocrinology, neuroendocrinology, and metabolism. For instance, treating experimental animals with it helps verify the differential regulation of LH and FSH synthesis by GnRH pulse frequency and clarify the mechanisms governing pituitary gonadotropin secretion.

4.2 Drug Development and Pharmacodynamic Evaluation Models

In reproductive drug development, it is used to establish disease models of ovulatory dysfunction, hyperandrogenism, estrogen deficiency, and others, enabling efficacy evaluation of novel contraceptives, ovulation-inducing agents, and sex hormone receptor modulators. Examples include establishing infertility models by suppressing ovulation in rats to test the follicle-activating effects of new ovulation inducers; and combining it with novel antitumor drugs in prostate cancer models to assess the antitumor activity of combination regimens. As a reference GnRH antagonist, it also supports potency, half-life, and side-effect comparisons with novel antagonists, providing a benchmark for drug screening.

4.3 Neuroendocrine and Behavioral Research

Recent studies have identified widespread distribution of GnRH receptors in the central nervous system (e.g., hypothalamus, hippocampus, amygdala), where they participate in neurotransmitter release, mood regulation, and cognitive function. At low doses, it crosses the blood-brain barrier and blocks central GnRH signaling, supporting research into GnRH modulation of anxiety, depression, learning, and memory. Animal experiments demonstrate that it attenuates haloperidol-induced catalepsy in rats, suggesting potential research value in neuropsychiatric disorders such as Parkinson's disease and schizophrenia.

5.1 Regulation of Livestock Reproductive Cycles

In livestock farming, antide acetate regulates estrous and ovulatory cycles in cattle, sheep, swine, and other livestock to achieve synchronized estrus and grouped breeding, improving production efficiency. For example, administration in cows suppresses follicular development and estrous behavior; upon cessation, ovarian function recovers synchronously to enable herd-wide estrus synchronization, facilitating artificial insemination and pregnancy management. It also provides temporary castration in male livestock by inhibiting testosterone secretion, reducing aggressive and mounting behaviors to improve fattening efficiency, with fertility restored after treatment to avoid stress and infection risks associated with surgical castration.

5.2 Experimental Animal Model Establishment

In breeding of laboratory animals (mice, rats, rabbits), the product is used to create infertility and sex hormone deficiency models for research in reproductive and developmental biology. Examples include establishing infertility models by suppressing ovulation in female mice to study embryo implantation and endometrial receptivity; and inhibiting spermatogenesis in male mice to investigate the pathogenesis and treatment of male infertility. It also supports reproductive control of laboratory animals to prevent unintended mating, ensuring animal quality and experimental data accuracy.

With its high efficacy, long duration, and favorable safety profile, the product has become a core drug in reproductive medicine and endocrine tumor therapy, with expanding applications in basic research and animal husbandry. Future development directions include:

Development of novel formulations such as long-acting microspheres and subcutaneous implants to extend dosing intervals to 1–3 months and improve patient compliance;

Optimization of combination therapies with targeted and immunotherapeutic agents to enhance outcomes in prostate and breast cancer and reduce drug resistance.

Expansion of new indications, exploring potential uses in polycystic ovary syndrome, postmenopausal osteoporosis, and neurodegenerative diseases;

Process optimization to lower synthesis costs, improve purity, and promote adoption in primary care and livestock farming.

In summary, as a third-generation GnRH antagonist, the product is applied across reproductive medicine, oncology, basic research, and animal breeding. It addresses key challenges in clinical care and assisted reproduction while serving as an essential tool for life science research. With advancing research and technological iteration, its application value will be further realized.